中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

29 records (took 0.019 seconds)

    TLR2 ANTAGONISTIC ANTIBODY AND USE THEREOF
    14.
    发明申请
    TLR2 ANTAGONISTIC ANTIBODY AND USE THEREOF 审中-公开
    TLR2拮抗抗体及其用途

    公开(公告)号：WO2005028509A1

    公开(公告)日：2005-03-31

    申请号：PCT/EP2004/010700

    申请日：2004-09-23

    Applicant: TECHNISCHE UNIVERSITAET MUENCHEN ,  KIRSCHNING, Carsten, Juergen ,  MENG, Guangxun ,  WAGNER, Hermann

    Inventor： KIRSCHNING, Carsten, Juergen ,  MENG, Guangxun ,  WAGNER, Hermann

    IPC: C07K16/00

    CPC classification number: C07K16/28 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2316/96 ,  C07K2317/33 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/76

    Abstract: The present invention is directed to a cross-reactive antibody, which specifically inhibits or blocks the mammalian Toll-like receptor 2 (TLR2)-mediated immune cell activation. The invention is further directed to an isolated nucleic acid or vector coding for the variable regions of the heavy and/or light chain of said antibody. It is further providing a pharmaceutical composition comprising said antibody, nucleic acid or vector and is directed to the use of said composition in the prevention and/or treatment of inflammatory processes or any other process induced by bacterial infection, trauma, or chronic inflammation, or for the prevention and/or treatment of bacteriaemia or sepsis.

    Abstract translation: 本发明涉及特异性抑制或阻断哺乳动物Toll样受体2（TLR2）介导的免疫细胞活化的交叉反应性抗体。 本发明还涉及编码所述抗体的重链和/或轻链的可变区的分离的核酸或载体。 进一步提供包含所述抗体，核酸或载体的药物组合物，并且涉及使用所述组合物预防和/或治疗由细菌感染，创伤或慢性炎症引起的炎症过程或任何其它过程，或 用于预防和/或治疗细菌性血症或败血症。

    BOROPHENE SYNTHESIS
    15.
    发明申请
    BOROPHENE SYNTHESIS 审中-公开

    公开(公告)号：WO2022171517A2

    公开(公告)日：2022-08-18

    申请号：PCT/EP2022/052594

    申请日：2022-02-03

    Applicant: UNIVERSITAET DER BUNDESWEHR MUENCHEN ,  TECHNISCHE UNIVERSITAET MUENCHEN

    Inventor： DUESBERG, Georg ,  AUWAERTER, Wilhelm ,  SACHDEV, Hermann ,  GONZÁLEZ CUXAT, Marc ,  SEUFERT, Knud Johannes ,  CHESNYAK, Valeria

    IPC: C01B35/02 ,  C01B35/023 ,  C01P2004/20

    Abstract: The invention relates to a method for the production of a structure containing at least one borophene, and/or at least one boron-heteroatom-domain comprising a 2D boron network, and/or a structure of a 2D-network containing a multitude of boron-containing clusters comprising B-B bonds, wherein at least one of the boron containing clusters comprising B-B bonds may comprise at least one heteroatom, and wherein the multitude of boron- containing clusters comprising B-B bonds are connected by B-B bonds or B-heteroatom bonds, preferably wherein one boron-containing cluster comprises 3 to 20 boron atoms, and/or a structure of a 2D-network containing a multitude of boron-heteroatom clusters having B-heteroatom bonds, wherein the multitude of boron-heteroatom clusters having B- heteroatom bonds are connected by B-B bonds, as well as a product comprising a structure containing at least one borophene, and/or at least one boron-heteroatom-domain comprising a 2D boron network, and/or a structure of a 2D-network containing a multitude of boron-containing clusters comprising B-B bonds, wherein at least one of the boron containing clusters comprising B-B bonds may comprise at least one heteroatom, and wherein the multitude of boron-containing clusters comprising B-B bonds are connected by B-B bonds or B-heteroatom bonds, preferably wherein one boron-containing cluster comprises 3 to 20 boron atoms, and/or a structure of a 2D-network containing a multitude of boron-heteroatom clusters having B-heteroatom bonds, wherein the multitude of boron-heteroatom clusters having B-heteroatom bonds are connected by B-B bonds.

    HEPATITIS B AND/OR HEPATITIS D-PERMISSIVE CELLS AND ANIMALS
    16.
    发明申请
    HEPATITIS B AND/OR HEPATITIS D-PERMISSIVE CELLS AND ANIMALS 审中-公开

    公开(公告)号：WO2019243564A1

    公开(公告)日：2019-12-26

    申请号：PCT/EP2019/066449

    申请日：2019-06-21

    Applicant: TECHNISCHE UNIVERSITAET MUENCHEN

    Inventor： PROTZER, Ulrike ,  WETTENGEL, Jochen ,  JESKE, Samuel ,  FISCHER, Konrad ,  SCHNIEKE, Angelika

    IPC: C07K14/705 ,  C12N5/071 ,  G01N33/569 ,  G01N33/576

    Abstract: The present invention relates to a porcine sodium taurocholate cotransporter polypeptide (NTCP) mutein, which has been modified at sequence positions 157-167 with the human sequence. This NTCP mutein renders a host cell and a transgenic animal susceptible for an infection with hepatitis B virus (HBV) and/or hepatitis D virus (HDV). The present invention further relates to a nucleic acid and a vector comprising the NTCP mutein of the invention. Also presented are methods for producing cells and transgenic animals, which are susceptible to HBV and/or HDV as well as uses of the NTCP mutein screening for compounds or rendering a cell susceptible for an infection with HBV and/or HDV. Additionally provided is a method for identifying a compound, which is useful in the prevention and/or treatment of HBV and/or HDV infection.

    MUTANT BETA-GLUCOSIDASE VARIANTS WITH INCREASED THERMOSTABILITY
    17.
    发明申请
    MUTANT BETA-GLUCOSIDASE VARIANTS WITH INCREASED THERMOSTABILITY 审中-公开
    具有增加的热稳定性的突变β-葡糖苷酶变体

    公开(公告)号：WO2017063787A1

    公开(公告)日：2017-04-20

    申请号：PCT/EP2016/070804

    申请日：2016-09-05

    Applicant: TECHNISCHE UNIVERSITAET MUENCHEN

    Inventor： ZVERLOV, Vladimir ,  SCHWARZ, Wolfgang ,  PRECHTL, Roman ,  LEIS, Benedikt ,  HELD, Claudia ,  LIEBL, Wolfgang

    IPC: C12N9/42

    CPC classification number: C12N9/2445 ,  C12Y302/01021

    Abstract: The invention relates to mutant variants of the β-glucosidase Cgl T from Thermoanaerobacter brockii and nucleic acids for producing the same. Said mutant variants show significantly increased thermostability and enzyme activity. Furthermore, the invention provides vectors, host cells and methods for producing said mutant variants of the β-glucosidase Cgl T. Also provided are artificial cellulosomes comprising the mutant variants of the β-glucosidase Cgl T and methods for the enzymatic hydrolysis of cellulosic biomass comprising said artificial cellulosomes and/or said mutant variants of the β-glucosidase Cgl T.

    Abstract translation: 本发明涉及来自布氏热厌氧杆菌的β-葡糖苷酶Cgl T的突变变体和用于生产它的核酸。 所述突变体变体显示显着增加的热稳定性和酶活性。 此外，本发明提供了用于产生β-葡糖苷酶Cgl的所述突变体变体的载体，宿主细胞和方法。还提供了包含β-葡萄糖苷酶Cgl T的突变体变体的人造纤维小体和用于纤维素生物质的酶水解的方法， 所述人造纤维素酶体和/或所述β-葡糖苷酶Cgl T的所述突变变体

    DIAGNOSIS KNOWLEDGE SHARING FOR SELF-HEALING
    20.
    发明申请
    DIAGNOSIS KNOWLEDGE SHARING FOR SELF-HEALING 审中-公开

    公开(公告)号：WO2020088747A1

    公开(公告)日：2020-05-07

    申请号：PCT/EP2018/079735

    申请日：2018-10-30

    Applicant: NOKIA SOLUTIONS AND NETWORKS OY ,  TECHNISCHE UNIVERSITAET MUENCHEN

    Inventor： ALI-TOLPPA, Janne Tapio ,  SCHULTZ, Benedek ,  KAJÓ, Márton

    IPC: H04L12/26 ,  H04L12/24

    Abstract: According to an aspect, there is provided a local diagnosis system comprising means for performing the following. The local diagnosis system detects one or more anomaly events associated with a communications network. Each anomaly event defines an anomaly pattern describing a data point in a performance indicator space. Then, the local diagnosis system updates one or more local cluster models to incorporate the one or more anomaly patterns within complexity constraints. Each of the one or more local cluster models corresponds to a different diagnosis label defining a diagnosis. In response to failing according to one or more pre-defined criteria to incorporate, in the updating, the one or more anomaly patterns to the one or more local cluster models, the local diagnosis system forwards at least the one or more local cluster models and one or more associated diagnosis labels to a central diagnosis system for further diagnosis.

Patent Agency Ranking